Analyzing Innocoll Holdings PLC (INNL) and The Competition
Innocoll Holdings PLC (NASDAQ: INNL) is one of 116 public companies in the “Pharmaceuticals” industry, but how does it contrast to its peers? We will compare Innocoll Holdings PLC to similar companies based on the strength of its earnings, risk, dividends, valuation, institutional ownership, profitability and analyst recommendations.
This table compares Innocoll Holdings PLC and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Innocoll Holdings PLC||-1,051.20%||N/A||-138.53%|
|Innocoll Holdings PLC Competitors||-2,925.59%||-70.76%||-9.78%|
Insider and Institutional Ownership
34.2% of Innocoll Holdings PLC shares are held by institutional investors. Comparatively, 42.4% of shares of all “Pharmaceuticals” companies are held by institutional investors. 11.7% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares Innocoll Holdings PLC and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Innocoll Holdings PLC||N/A||N/A||-1.42|
|Innocoll Holdings PLC Competitors||$8.39 billion||$1.12 billion||133.87|
Innocoll Holdings PLC’s peers have higher revenue and earnings than Innocoll Holdings PLC. Innocoll Holdings PLC is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This is a breakdown of recent ratings and price targets for Innocoll Holdings PLC and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Innocoll Holdings PLC||0||3||1||0||2.25|
|Innocoll Holdings PLC Competitors||846||3755||6778||185||2.54|
Innocoll Holdings PLC presently has a consensus target price of $4.50, suggesting a potential upside of 91.49%. As a group, “Pharmaceuticals” companies have a potential upside of 21.38%. Given Innocoll Holdings PLC’s higher possible upside, analysts plainly believe Innocoll Holdings PLC is more favorable than its peers.
Innocoll Holdings PLC peers beat Innocoll Holdings PLC on 7 of the 10 factors compared.
Innocoll Holdings PLC Company Profile
Innocoll Holdings Public Limited Company is a commercial-stage specialty pharmaceutical and medical device company with late-stage development programs. The Company operates through the segment of manufacture and sale of collagen-based pharmaceutical products. It utilizes collagen-based technology platform to develop its biodegradable and bioresorbable products and product candidates, which can be broken down by the body without the need for surgical removal or applied topically. Using its processes at its manufacturing facility, it derives and purifies bovine and equine collagen and then utilizes its technology platform to incorporate the purified collagen into its topical and implantable products. Its lead product candidates are XaraColl for the treatment of post-operative pain and Cogenzia for the treatment of diabetic foot infections. Its marketed products include CollaGUARD, Collatamp, Septocoll and RegenePro. It has initiated its Phase III efficacy trials for Cogenzia.
Receive News & Ratings for Innocoll Holdings PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innocoll Holdings PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.